SEC Form 4 · accession 0001562180-18-000729
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Lefkoff
Director
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2018 | M | 25,000 | $5.60 | A | 42,720 | D | |
| Common Stock | Feb 9, 2018 | M | 25,000 | $3.87 | A | 67,720 | D | |
| Common StockF1 | Feb 9, 2018 | S | 50,000 | $17.01 | D | 17,720 | D | |
| Common StockF2 | holding | — | — | — | 45,000 | I | see footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.60 | Feb 9, 2018 | M | 25,000 | D | Oct 23, 2014 | Oct 23, 2023 | Common Stock | 25,000 | 0 | D |
| Stock Option (Right to Buy) | $3.87 | Feb 9, 2018 | M | 25,000 | D | Oct 30, 2015 | Oct 30, 2024 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
- F2Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.